

Amendments to the Claims:

Claims 1-7 (Canceled)

8. (Currently amended) A ~~The compound of claim 51 which is or salt that is~~ selected from the following compounds and their pharmaceutically acceptable salts:
- ~~6-[2-(4-benzo[d]isoxazol-3-yl-piperazin-1-yl)-ethyl]-4-methyl-3,4-dihydro-1H-quinolin-2-one;~~
- ~~6-[2-(4-benzo[d]isoxazol-3-yl-piperazin-1-yl)-ethyl]-4S-methyl-3,4-dihydro-1H-quinolin-2-one;~~
- ~~6-[2-(4-benzo[d]isoxazol-3-yl-piperazin-1-yl)-ethyl]-4R-methyl-3,4-dihydro-1H-quinolin-2-one;~~
- ~~6-[2-(4-benzo[d]isoxazol-3-yl-piperazin-1-yl)-ethyl]-1,4-dimethyl-3,4-dihydro-1H-quinolin-2-one;~~
- ~~6-[2-(4-benzo[d]isoxazol-3-yl-piperazin-1-yl)-ethyl]-4,4-dimethyl-3,4-dihydro-1H-quinolin-2-one;~~
- ~~6-[2-(4-benzo[d]isoxazol-3-yl-piperazin-1-yl)-ethyl]-1,4,4-trimethyl-3,4-dihydro-1H-quinolin-2-one;~~
- ~~6-[2-(4-benzo[d]isothiazol-3-yl-piperazin-1-yl)-ethyl]-4,4,8-trimethyl-3,4-dihydro-1H-quinolin-2-one;~~
- ~~6-[2-(4-benzo[d]isoxazol-3-yl-piperazin-1-yl)-ethyl]-3-methyl-3,4-dihydro-1H-quinolin-2-one;~~
- ~~6-[2-(4-benzo[d]isoxazol-3-yl-piperazin-1-yl)-ethyl]-3,3-dimethyl-3,4-dihydro-1H-quinolin-2-one;~~
- ~~6-[2-(4-benzo[d]isoxazol-3-yl-piperazin-1-yl)-ethyl]-3,4-dimethyl-3,4-dihydro-1H-quinolin-2-one;~~
- ~~6-[2-(4-benzo[d]isoxazol-3-yl-piperazin-1-yl)-ethyl]-1,3,3,4,4-pentamethyl-3,4-dihydro-1H-quinolin-2-one;~~
- ~~6-[2-(4-benzo[d]isoxazol-3-yl-piperazin-1-yl)-ethyl]-3,3,4-trimethyl-3,4-dihydro-1H-quinolin-2-one;~~

~~6-[2-[4-(1H-indazol-3-yl)-piperazin-1-yl]-ethyl]-4-methyl-3,4-dihydro-1H-quinolin-2-one;~~

~~6-[2-[4-(1H-indazol-3-yl)-piperazin-1-yl]-ethyl]-4,4-dimethyl-3,4-dihydro-1H-quinolin-2-one;~~

~~6-[2-[4-(1H-indazol-3-yl)-piperazin-1-yl]-ethyl]-3-methyl-3,4-dihydro-1H-quinolin-2-one;~~

~~6-[2-[4-(1H-indazol-3-yl)-piperazin-1-yl]-ethyl]-3,3-dimethyl-3,4-dihydro-1H-quinolin-2-one;~~

~~6-[2-[4-(1H-indazol-3-yl)-piperazin-1-yl]-ethyl]-3,4-dimethyl-3,4-dihydro-1H-quinolin-2-one;~~

~~6-[2-(4-benzo[d]isothiazol-3-yl-piperazin-1-yl)-ethyl]-1,3,3,4,4-pentamethyl-3,4-dihydro-1H-quinolin-2-one;~~

~~6-[2-(4-benzo[d]isothiazol-3-yl-piperazin-1-yl)-ethyl]-3,3,4-trimethyl-3,4-dihydro-1H-quinolin-2-one;~~

~~6-[2-(4-Benzo[d]isothiazol-3-yl-piperazin-1-yl)-ethyl]-4,4,8-trimethyl-3,4-dihydro-1H-quinolin-2-one, mesylate salt;~~

~~6-[2-(4-Benzo[d]isothiazol-3-yl-piperazin-1-yl)-ethyl]-7-chloro-4,4,8-trimethyl-3,4-dihydro-1H-quinolin-2-one methanesulfonate;~~

~~6-[2-(4-Benzo[d]isothiazol-3-yl-piperazin-1-yl)-ethyl]-7-fluoro-4,4,8-trimethyl-3,4-dihydro-1H-quinolin-2-one hydrochloride;~~

~~6-[3-[4-(1H-indazol-3-yl)-piperazin-1-yl]-propyl]-4,4-dimethyl-3,4-dihydro-1H-quinolin-2-one;~~

~~7-chloro-6-[3-(4-1,2-benzisothiazol-3-yl-piperazin-1-yl)-propyl]-4,4-dimethyl-3,4-dihydro-1H-quinolin-2-one;~~

~~7-chloro-6-[3-(4-1,2-benzisoxazol-3-yl-piperazin-1-yl)-propyl]-4,4-dimethyl-3,4-dihydro-1H-quinolin-2-one;~~

~~6-[3-(4-1,2-benzisothiazol-3-yl-piperazin-1-yl)-propyl]-4-methyl-3,4-dihydro-1H-quinolin-2-one;~~

~~6-[3-(4-1,2-benzisoxazol-3-yl-piperazin-1-yl)-propyl]-4-methyl-3,4-dihydro-1H-quinolin-2-one;~~

~~6-[3-[4-(1H-indazol-3-yl)-piperazin-1-yl]-propyl]-4-methyl-3,4-dihydro-1H-quinolin-2-one;~~

~~6-[3-(4-1,2-benzisothiazol-3-yl-piperazin-1-yl)-propyl]-3,3-dimethyl-3,4-dihydro-1H-quinolin-2-one;~~

~~6-[3-(4-1,2-benzisoxazol-3-yl-piperazin-1-yl)-propyl]-3,3-dimethyl-3,4-dihydro-1H-quinolin-2-one;~~

~~6-[3-[4-(1H-indazol-3-yl)-piperazin-1-yl]-propyl]-3,3-dimethyl-3,4-dihydro-1H-quinolin-2-one;~~

~~6-[3-(4-1,2-benzisothiazol-3-yl-piperazin-1-yl)-propyl]-3-methyl-3,4-dihydro-1H-quinolin-2-one;~~

~~6-[3-(4-1,2-benzisoxazol-3-yl-piperazin-1-yl)-propyl]-3-methyl-3,4-dihydro-1H-quinolin-2-one; and~~

~~6-[3-[4-(1H-indazol-3-yl)-piperazin-1-yl]-propyl]-3-methyl-3,4-dihydro-1H-quinolin-2-one.~~

Claims 9-12 (Canceled)

13. (Previously presented) A pharmaceutical composition comprising an amount of a compound according to claim 49, or a pharmaceutically acceptable salt thereof, and a pharmaceutically acceptable carrier.

14. (Withdrawn) A method for treating a disorder or condition selected from bipolar disorders or manic depression, for example, bipolar I disorder, and bipolar II disorder, or schizophrenia and other psychotic disorders, for example, schizophreniform disorders, schizoaffective disorders, delusional disorders, brief psychotic disorders, shared psychotic disorders, psychotic disorders with delusions or hallucinations, psychotic episodes of anxiety, anxiety associated with psychosis, psychotic mood disorders such as severe major depressive disorder, mood disorders associated with psychotic disorders such as acute mania and depression associated with bipolar disorder, mood disorders associated with schizophrenia, delirium, dementia, and

~~amnesic and other cognitive or neurodegenerative disorders, such as Parkinson's disease (PD), Huntington's disease (HD), Alzheimer's disease, senile dementia, dementia of the Alzheimer's type, memory disorders, loss of executive function, vascular dementia, and other dementias, for example, due to HIV disease, head trauma, Parkinson's disease, Huntington's disease, Pick's disease, Creutzfeldt-Jakob disease, or due to multiple etiologies; movement disorders such as akinesias, dyskinesias, including familial paroxysmal dyskinesias, spasticities, Tourette's syndrome, Scott syndrome, PALSYS and akinetic-rigid syndrome; extra-pyramidal movement disorders such as medication-induced movement disorders, for example, neuroleptic-induced Parkinsonism, neuroleptic malignant syndrome, neuroleptic-induced acute dystonia, neuroleptic-induced acute akathisia, neuroleptic-induced tardive dyskinesia and medication-induced postural tremour; chemical dependencies and addictions (e.g., dependencies on, or addictions to, alcohol, heroin, cocaine, benzodiazepines, nicotine, or phenobarbital) and behavioral addictions such as an addiction to gambling; and ocular disorders such as glaucoma and ischemic retinopathy in a mammal, including a human, comprising administering to a the mammal in need of such treatment an amount of a compound according to claim 149, or a pharmaceutically acceptable salt thereof, that is effective in treating such disorder or condition.~~

15. (Withdrawn) A method according to claim 14, wherein the disorder or condition that is being treated is selected from ~~major depression, single-episode depression, recurrent depression, child abuse induced depression, postpartum depression, dysthymia, cyclothymia and bipolar disorder.~~

16. (Withdrawn) A method according to claim 14, wherein the disorder or condition that is being treated is selected from ~~schizophrenia, schizoaffective disorder, delusional disorder, substance-induced psychotic disorder, brief psychotic disorder, shared psychotic disorder, psychotic disorder due to a general medical condition, and schizophreniform disorder.~~

Claim 17-30 (Canceled)

31. (Previously presented) A pharmaceutical composition comprising an amount of a compound according to claim 50 and a pharmaceutically acceptable carrier.

Claim 32-48 (Canceled)

49. (Currently amended) A compound which is 6-[2-(4-benzo[d]isothiazol-3-yl-piperazin-1-yl)-ethyl]-8-chloro-4,4-dimethyl-3,4-dihydro-1H-quinolin-2-one ~~and~~or pharmaceutically acceptable salts thereof.

50. (Currently amended) ~~A~~The compound of claim 49 which is 6-[2-(4-benzo[d]isothiazol-3-yl-piperazin-1-yl)-ethyl]-8-chloro-4,4-dimethyl-3,4-dihydro-1H-quinolin-2-one hydrochloride.

51. (New) A compound which is 6-[2-(4-Benzo[d]isothiazol-3-yl-piperazin-1-yl)-ethyl]-7-chloro-4,4,8-trimethyl-3,4-dihydro-1H-quinolin-2-one or pharmaceutically acceptable salts thereof.

52. (New) A pharmaceutical composition comprising an amount of a compound according to claim 8 and a pharmaceutically acceptable carrier.

53. (New) A pharmaceutical composition comprising an amount of a compound according to claim 51, or a pharmaceutically acceptable salt thereof, and a pharmaceutically acceptable carrier.